Tuesday 16 June 2020, Amsterdam
A vaccine is a biological preparation that provides a specific infectious disease with successfully acquired immunity. It includes an agent that imitates a microorganism that causes disease and is often made of weakened or killed forms of the microbe, its toxins, or one of its surface proteins. The agent activates the body's immune system to identify the agent as a threat, kill it, and further identify and kill any of the microorganisms that might be associated with that agent in the future. The vaccine market is highly regulated and relies primarily on public buyers and donor policies. The market for vaccines has very distinctive features that increase the complexity of pricing and procurement assessment.
Some of the key challenges in the vaccine market are the maintenance of adequate immunization coverage, which is a major issue for many governments around the world. Many developing countries have poor surveillance technology, inadequate data on disease incidence, and a poor knowledge base. In addition, many children in developing countries suffer from malnutrition (deficiencies in zinc, vitamin A, and selenium), parasite infection, multiple infections with more than one pathogen, and mucosal abnormalities such as persistent rhinitis in the gut. It is essential to maintain a political commitment to ensure the vaccination infrastructure in the face of competing priorities and the continued affordability of vaccines.
Development of vaccines is difficult, complex, highly risky, and costly and includes the development of clinical development, process development, and assays. The risk is high since most candidates for the vaccine fail in preclinical or early clinical development. Clinical development helps analyze the safety, immunogenicity, and efficacy effects of vaccines on patients through a 3-stage process. The design of the process includes making test vaccine preparations that satisfy regulatory criteria for clinical research, and eventually scale-up methods that contribute to a stable full-scale production process. The creation of assays includes different methods for checking the purity of raw materials, the safety and potency of the vaccine product, and immunologic and other vaccine efficacy parameters. Go / no-go decisions must be taken at any point in clinical and process growth and should be informed by evidence. Development tasks in clinical, process and assay are closely integrated.
In some countries, vaccinations are voluntary and in others compulsory, with compulsory vaccination policies sometimes leading to the opposition. In a national vaccination schedule, some governments pay for all or part of the cost of vaccinations. Vaccination cost-benefit analyzes have shown that there is an economic incentive to implement vaccination policies since vaccinations can save a significant number of lives and costs.
The report titled “Global Vaccine- Market and Technology Forecast to 2028
” is segmented by Region, by Technology, by Type. The Regional Segments are North America, Europe, APAC, Middle East, and ROW. The Technology market is sub segmented as Conjugate Vaccines, Inactivated and subunit Vaccines, Live attenuated Vaccines, Recombinant Vaccines, Toxoid Vaccines. By Patient Type, the market is segmented by Pediatric patients and Adult patients.
The total Global market for vaccine is estimated at around USD 75 Billion in 2020 and the market is expected to grow to around USD 123 Billion by 2028. The CAGR of the market is accounted at around 6.4%. By region, North America is expected to have the largest market for Vaccines and APAC region is expected to be the fastest growing market.
The report “Global Vaccine- Market and Technology Forecast to 2028” is segmented based on Region, Technology, and Patient Type. The study period is 2018- 2028 and the forecast period is 2020-2028.
Reasons to Buy:
- The report would help any new entrants into the market to identify the key trends which would impact the market during the forecast period, 2020-2028.
- The report covers all the drivers, restraint, and challenges in the Vaccine market in detailed.
- The new entrants in the market would understand the key historical demand across the countries.
- The country analysis section has been segmented by type of small arm.
- The key technologies that are expected to shape the market during the forecast period are covered in detailed.
- The report would help the existing players to understand the future market potential across types and Geographies.
- The sales team of vaccine manufacturers could this report for their sales planning over the next few years and plan Region specific strategies.
- The investment bankers focused on this sector could use the report to identify hot spots in this market.
ASDReports.com Media contact: S. Koopman -
Marketing and Communications
ASDReports.com / ASDMedia BV - Veemkade 356 - 1019HD Amsterdam - The Netherlands
P : +31(0)20 486 1286 - F : +31(0)20 486 0216 - E : email@example.com
back to News